WM-8014: Selective KAT6A/B Inhibitor for Epigenetic Research

Executive Summary: WM-8014 is a highly potent, reversible, and competitive inhibitor of the histone acetyltransferases KAT6A and KAT6B, with reported IC₅₀ values of 8 nM and 28 nM, respectively (RESTRICT-seq, 2025). The compound acts by directly competing with acetyl-CoA at the MYST domain binding site, effectively blocking acetyltransferase activity. WM-8014 induces cell cycle arrest and promotes senescence via the p16^INK4A–p19^ARF pathway in mouse embryonic fibroblasts, without causing general cytotoxicity (APExBIO). In vivo, it selectively suppresses KRAS G12V-driven hepatocellular overproliferation in zebrafish while sparing normal tissue growth. The product is distributed by APExBIO and is a preferred choice for researchers investigating epigenetic regulation and oncogene-induced senescence.

Biological Rationale

Epigenetic regulation via histone acetylation is essential for chromatin remodeling, gene expression, and cellular identity (RESTRICT-seq, 2025). KAT6A and KAT6B are members of the MYST family of lysine acetyltransferases, responsible for the acetylation of histone H3 at lysine 9 and lysine 14. Mutations, amplifications, or overexpression of KAT6A/B are implicated in various malignancies, including acute myeloid leukemia and solid tumors (acetyl-angiotensinogen.com). Precise inhibition of KAT6A/B is essential to dissect their role in oncogene-induced senescence and proliferation. WM-8014 provides a highly selective, reversible, and competitive tool for such studies.

Mechanism of Action of WM-8014

WM-8014 functions as a competitive, reversible inhibitor of KAT6A (MOZ), KAT6B (MORF/QKF), KAT5, and KAT7, binding directly to the acetyl-CoA-binding site on the MYST domain. The compound's acyl sulfonyl hydrazide moiety forms hydrogen bonds similar to those of the acetyl-CoA diphosphate group, effectively occupying the substrate-binding domain and inhibiting enzymatic transfer of acetyl groups to lysine residues (APExBIO). WM-8014 exhibits the following IC₅₀ values under standard in vitro assay conditions (25°C, pH 7.4, Tris buffer):

• KAT6A: 8 nM
• KAT6B: 28 nM
• KAT5: 224 nM
• KAT7: 342 nM

Direct competition with acetyl-CoA results in potent inhibition of histone acetyltransferase activity. Unlike general cytotoxic agents, WM-8014 leads to cell cycle arrest and senescence via the upregulation of Cdkn2a (encoding p16^INK4A and p19^ARF) and downregulation of DNA replication genes such as Cdc6 in MEFs (RESTRICT-seq, 2025).

Evidence & Benchmarks

• WM-8014 demonstrates nanomolar inhibition of KAT6A (IC₅₀=8 nM) and KAT6B (IC₅₀=28 nM) in biochemical assays (DOI).
• In mouse embryonic fibroblasts, WM-8014 treatment upregulates Cdkn2a mRNA and downregulates the KAT6A target gene Cdc6, confirmed by RNA-seq after 24 hours exposure at 1 μM (DOI).
• In zebrafish models of KRAS G12V-induced hepatocellular proliferation, WM-8014 (0–20 μM) reduces liver volume and S phase entry without affecting normal liver development (DOI).
• WM-8014 shows high selectivity for KAT6A/B over KAT5/KAT7, as evidenced by its >10-fold higher IC₅₀ for the latter enzymes (APExBIO).
• High plasma-protein binding limits in vivo efficacy in mice; the derivative WM-1119 is recommended for such studies (APExBIO).

Applications, Limits & Misconceptions

WM-8014 is optimized for cellular and in vivo models of epigenetic regulation, oncogene-induced senescence, and cell cycle arrest in cancer biology research. Its competitive inhibition at the acetyl-CoA binding site makes it ideal for dissecting the roles of KAT6A/B in chromatin-dependent processes (RNA Clean). In contrast to previous reviews, this article provides updated benchmarks and clarifies the compound's selectivity and in vivo limitations, especially regarding plasma protein binding.

Common Pitfalls or Misconceptions

• WM-8014 is not a pan-acetyltransferase inhibitor: It is highly selective for KAT6A/B, with markedly lower potency for KAT5 and KAT7.
• Not recommended for long-term in vivo mouse studies: High plasma protein binding reduces efficacy; use WM-1119 for such studies.
• Solubility limitations: WM-8014 is insoluble in ethanol and water above 16 μM, but highly soluble in DMSO (≥76.1 mg/mL).
• Does not cause general cytotoxicity: Its effect is senescence-specific via the p16^INK4A–p19^ARF pathway, not broad cell death.
• Not a suitable substitute for pan-HAT inhibitors in global acetylation studies: Use only when KAT6A/B-specific effects are desired.

Workflow Integration & Parameters

WM-8014 is supplied by APExBIO as the A8779 kit (WM-8014 product page). For in vitro applications, dissolve in DMSO to a stock concentration of up to 76.1 mg/mL (approx. 150 mM) and dilute into aqueous buffers for final assay concentrations (typically 0.1–10 μM). Avoid prolonged storage of solutions; store dry powder at -20°C. For cell cycle arrest and senescence assays, treat cells for 24–72 hours at 1–5 μM under standard culture conditions. In vivo studies in zebrafish use 0–20 μM concentrations in embryo medium. For comparative protocol guidance, see this workflow article, which details cell viability and proliferation endpoints; the current article extends this with updated in vivo limitations and mechanistic benchmarks.

For chromatin immunoprecipitation (ChIP) or RNA-seq readouts, synchronize treatment timing with anticipated epigenetic changes (Histone H2A guide), which this article clarifies with direct benchmarks from recent preclinical research.

Conclusion & Outlook

WM-8014 remains the gold-standard selective KAT6A/B inhibitor for epigenetic research, enabling oncogene-induced senescence modeling, cell cycle arrest assays, and functional genomics. The compound's competitive acetyl-CoA site inhibition, robust selectivity, and non-cytotoxicity profile position it as a critical tool for cancer biology and drug target validation. Researchers should be mindful of its solubility and species-specific pharmacokinetic considerations. Future directions include the use of structural analogs such as WM-1119 for in vivo mammalian studies and expanded benchmarking in combination with CRISPR and RESTRICT-seq workflows (RESTRICT-seq, 2025).